|Bid||164.99 x 800|
|Ask||165.01 x 1000|
|Day's range||160.73 - 165.15|
|52-week range||133.65 - 179.92|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||24.80|
|Forward dividend & yield||4.24 (2.63%)|
|Ex-dividend date||23 Aug 2021|
|1y target est||N/A|
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed industry veteran Bruce Cousins as the Company's new President and Chief Financial Officer.
Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union's 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful approval or authorization by the national regulatory authorities of AU member states.
MOSCOW, Dec. 14, 2020 /CNW/ -- The Global Energy Association presented its first annual report entitled "Ten breakthrough ideas in energy for the next 10 years.